In conclusion, we have generated a novel mAb specific for VEGFR-1 that displays potent in vivo antitumor activity, as a result of different effects: antiangiogenic activity, inhibition of tumor cell migration and vasculogenic mimicry, down-modulation of monocyte/macrophage recruitment to the tumor area and of myeloid progenitor mobilization from the bone marrow (Figure 8). Here, FLT1 is linked to neoplasm.